The article discusses the ongoing lack of compensation for women harmed by pelvic mesh implants and families affected by the epilepsy drug valproate, despite plans for financial redress being outlined by England's patient safety commissioner two years ago. The article suggests uncertainty and delays in providing the promised compensation.